BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7934365)

  • 1. Ciprofibrate and lipid profile.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1994 Oct; 344(8927):955. PubMed ID: 7934365
    [No Abstract]   [Full Text] [Related]  

  • 2. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibrate monotherapy and profound hypoalphalipoproteinaemia.
    Olukoga AO; Crowley VE; Stewart MF; Weinkove O
    Postgrad Med J; 1996 Mar; 72(845):189. PubMed ID: 8731722
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ciprofibrate-induced acute cholestatic hepatitis].
    Pflumio F; Andrès E; Ubrich M; Geisler F; Imbs JL; Di Liberatore M
    Ann Endocrinol (Paris); 2003 Jun; 64(3):232-3. PubMed ID: 12910067
    [No Abstract]   [Full Text] [Related]  

  • 5. [Acute rhabdomyolysis during treatment with ciprofibrate].
    Delangre T; Vernier L; Moore N; Mihout B
    Presse Med; 1990 Nov; 19(39):1811-2. PubMed ID: 2148009
    [No Abstract]   [Full Text] [Related]  

  • 6. [Acute severe fibrosing hepatitis associated with ciprofibrate treatment].
    Dumortier J; Slim R; Chevallier M; Boillot O; Thaunat JL; Vaillant E; Vial T; Bellemin B; Paliard P; Scoazec JY
    Gastroenterol Clin Biol; 1999 Dec; 23(12):1399-400. PubMed ID: 10642628
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin].
    Blain H; Klein M; Weryha G; Tréchot P; Hanesse B; Leclère J
    Rev Med Interne; 1996; 17(10):859-60. PubMed ID: 8976986
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cytolytic hepatic damage caused by ciprofibrate].
    Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
    Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
    Fontaine C; Guiard-Schmid JB; Slama L; Essid A; Lukiana T; Rondeau E; Pialoux G
    AIDS; 2005 Nov; 19(16):1927-8. PubMed ID: 16227807
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment.
    Ramachandran S; Giles PD; Hartland A
    BMJ; 1997 May; 314(7094):1593. PubMed ID: 9186171
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP; Jagroon IA
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract]   [Full Text] [Related]  

  • 13. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 14. [Does hypothyroidism predispose muscular toxicity of fibrates?].
    Tregouet B
    Rev Med Interne; 1991; 12(2):159. PubMed ID: 1853004
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrates and renal function.
    Gajdos M; Dzúrik R
    Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864
    [No Abstract]   [Full Text] [Related]  

  • 16. [Myositis, hypothyroidism and fibrates].
    Wechsler B; Doumith R; Weil M
    Rev Med Interne; 1991; 12(6):475. PubMed ID: 1792441
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 18. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
    Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
    Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C
    Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.